Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terazosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | GLA | P06280 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.98 |
| ▸ | HPGD | P15428 | 4/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | DRD1 | P21728 | 2/20 | 0.96 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.96 |
| ▸ | TP53 | P04637 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terazosin SCHEMBL1172921 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL8540346 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL5421873 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL29361818 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL5918282 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL9079964 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL9195360 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL9053035 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL41544 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD | |
| Terazosin SCHEMBL8540336 | 1.00 | KDM4E (1.00) | KDM4EGLAGAAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114404380-B | Terazosin hydrochloride capsule and preparation method thereof | 重庆华森制药股份有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-114404380-A | Terazosin hydrochloride capsule and preparation method thereof | 重庆华森制药股份有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-113730413-A | Application of terazosin in preparation of medicines for reducing blood vessel hardness | 张存泰 | 2021-12-03 | — | — | CN | claimed |
| CN-104840436-A | Medicine composition | LIU LEI | 2015-08-19 | — | — | CN | claimed |
| US-5952003-A | TERAZOSIN DOSAGE FORM CAPSULES CONTAINING SOLID FILL WHICH ARE BIOEQUIVALENT TO A REFERENCE LIQUID-FILLED TERAZOSIN CAPSULE DOSAGE FORM, BUT HAVE IMPROVED SHELF LIFE AND ARE SIMPLER TO MANUFACTURE | NOVARTIS CORPORATION (US) | 1999-09-14 | — | — | US | claimed |
| WO-1998005308-A2 | TERAZOSIN CAPSULES | NOVARTIS AG (CH) | 1998-02-12 | — | — | WO | claimed |
| US-5675006-A | REACTING INTERMEDIATE WITH PIPERAZINE OR 1,4-DIAZAPINE DERIVATIVES OR AMMONIA TO FORM CHEMICAL INTERMEDIATE, CLOSING THE RING | BRANTFORD CHEMICALS INC. (CA) | 1997-10-07 | — | — | US | claimed |
| EP-0656885-A1 | SYNTHESIS OF 2-SUBSTITUTED QUINAZOLINE COMPOUNDS (SUCH AS TERAZOSIN) AND MEOBENTINE AND BETHANIDINE AND INTERMEDIATES THEREFOR | ACIC (CANADA) INC. (CA) | 1995-06-14 | — | — | EP | claimed |
| WO-1994005628-A1 | SYNTHESIS OF 2-SUBSTITUTED QUINAZOLINE COMPOUNDS (SUCH AS TERAZOSIN) AND MEOBENTINE AND BETHANIDINE AND INTERMEDIATES THEREFOR | ACIC (CANADA) INC. (CA) | 1994-03-17 | — | — | WO | claimed |
| CN-114404380-B | Terazosin hydrochloride capsule and preparation method thereof | 重庆华森制药股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-114404380-A | Terazosin hydrochloride capsule and preparation method thereof | 重庆华森制药股份有限公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3220942-B1 | COMPOSITIONS COMPRISING LOW DOSE DESMOPRESSIN IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST | SERENITY PHARMACEUTICALS LLC (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-113730413-A | Application of terazosin in preparation of medicines for reducing blood vessel hardness | 张存泰 | 2021-12-03 | — | — | CN | disclosed |
| US-10646447-B2 | Oral sustained-release triple layer tablet | GL PHARMTECH CORP. (KR) | 2020-05-12 | — | — | US | disclosed |
| WO-1995031200-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING GLAUCOMA CONTAINING TERAZOSIN | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1995-11-23 | — | — | WO | disclosed |
| EP-0656885-A1 | SYNTHESIS OF 2-SUBSTITUTED QUINAZOLINE COMPOUNDS (SUCH AS TERAZOSIN) AND MEOBENTINE AND BETHANIDINE AND INTERMEDIATES THEREFOR | ACIC (CANADA) INC. (CA) | 1995-06-14 | — | — | EP | disclosed |
| WO-1994005628-A1 | SYNTHESIS OF 2-SUBSTITUTED QUINAZOLINE COMPOUNDS (SUCH AS TERAZOSIN) AND MEOBENTINE AND BETHANIDINE AND INTERMEDIATES THEREFOR | ACIC (CANADA) INC. (CA) | 1994-03-17 | — | — | WO | disclosed |
| US-5268182-A | Coating contains ethyl cellulose or methyl methacrylate; plasticizer and detackifying agent | ABBOTT LABORATORIES (US) | 1993-12-07 | — | — | US | disclosed |
| US-5169642-A | Coating of ethyl cellulose and(or) methyl methacrylate with plasticizer and detackifier agent | ABBOTT LABORATORIES (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0430287-A2 | Sustained-release drug dosage units | ABBOTT LABORATORIES (US) | 1991-06-05 | — | — | EP | disclosed |